Contract Manufacturing of Biopharmaceuticals Including Antibodies or Antibody Fragments

Modern Biopharmaceuticals: Design, Development and Optimization

Volumn 3, Issue , 2008, Pages 1083-1101

  Hempel, J Carsten ^a   Hess, Philipp N ^b  

^a Chemgineering GmbH   (Germany)

^b NONE   (Netherlands)

Author keywords

Bioverfahrenstechnik; Fragments; Glycoprotein; Hamster; Outsourcing

Indexed keywords

EID: 84890004131     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620982.ch46     Document Type: Chapter

References (12)

1. Milstein C, Köhler G. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256: 495-497.
2. Cacciuttolo MA, et al. Large-Scale Production of a Monoclonal IgM in a Hybridoma Suspension Culture. BioPharm 1998, 11(4): 20-27.
3. Wurm FM. Development of High-Yielding Cell Culture processes for medical applications: How to meet the challenge. Presented at Scale-Up of Biopharmaceutical Products, NL-Amsterdam, IBC Life Science UK, 26-27 January, 2004.
4. Yokota T, Milenic DE, Whitlow M, and Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992, 52: 3402-3408.
5. Harrison JS and Keshavarz-Moore E. Production of antibody fragments in Escherichia coli. Ann NY Acad Sci 1996, 782: 143-158.
6. Kara B. Challenges and solutions: Scale-up of microbial production systems. Basel Switzerland, 24 January 2003 (IBC Life Sciences, London, UK).
7. Pisano GP. The Development Factory: Unlocking the potential of process innovation. Harvard Business School Presentation, Boston, MA, 1997, pp. 1-343.
8. DiMasi JA. The value of improving the productivity of the drug development process: Faster times and better decisions. Pharmacoeconomics 2002, 20 (Suppl.) 3: 1-10.
9. Neway JO. How the data ecosystem affects process development and the bottom line. Bio-Process Int 2004, 2(5): 82-91.
10. DiMasi JA, Hansen RW, and Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003, 22: 151-185.
11. Booth R. Extending your enterprise with outsourcing. BioProcess Int 2003, 1(10): 14-18.
12. US Department of Health and Human Services Food and Drug Administration: Challenge and Opportunity on the Critical Path to New Medical Products, March 2004.